Literature DB >> 23136221

Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

Ruchi M Newman1, Thomas Kuntzen, Brian Weiner, Andrew Berical, Patrick Charlebois, Carla Kuiken, Donald G Murphy, Peter Simmonds, Phil Bennett, Niall J Lennon, Bruce W Birren, Michael C Zody, Todd M Allen, Matthew R Henn.   

Abstract

BACKGROUND: Infection with hepatitis C virus (HCV) is a burgeoning worldwide public health problem, with 170 million infected individuals and an estimated 20 million deaths in the coming decades. While 6 main genotypes generally distinguish the global geographic diversity of HCV, a multitude of closely related subtypes within these genotypes are poorly defined and may influence clinical outcome and treatment options. Unfortunately, the paucity of genetic data from many of these subtypes makes time-consuming primer walking the limiting step for sequencing understudied subtypes.
METHODS: Here we combined long-range polymerase chain reaction amplification with pyrosequencing for a rapid approach to generate the complete viral coding region of 31 samples representing poorly defined HCV subtypes.
RESULTS: Phylogenetic classification based on full genome sequences validated previously identified HCV subtypes, identified a recombinant sequence, and identified a new distinct subtype of genotype 4. Unlike conventional sequencing methods, use of deep sequencing also facilitated characterization of minor drug resistance variants within these uncommon or, in some cases, previously uncharacterized HCV subtypes.
CONCLUSIONS: These data aid in the classification of uncommon HCV subtypes while also providing a high-resolution view of viral diversity within infected patients, which may be relevant to the development of therapeutic regimens to minimize drug resistance.

Entities:  

Keywords:  Hepatitis C virus; drug resistance mutations; pyrosequencing; subtype classification; viral diversity

Mesh:

Substances:

Year:  2012        PMID: 23136221      PMCID: PMC3666132          DOI: 10.1093/infdis/jis679

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.

Authors:  Maxwell D Cummings; Jimmy Lindberg; Tse-I Lin; Herman de Kock; Oliver Lenz; Elisabet Lilja; Sara Felländer; Vera Baraznenok; Susanne Nyström; Magnus Nilsson; Lotta Vrang; Michael Edlund; Asa Rosenquist; Bertil Samuelsson; Pierre Raboisson; Kenneth Simmen
Journal:  Angew Chem Int Ed Engl       Date:  2010-02-22       Impact factor: 15.336

2.  Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV.

Authors:  S Akhavan; A Schnuriger; P Lebray; Y Benhamou; T Poynard; V Thibault
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

3.  Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.

Authors:  F Xavier López-Labrador; Andrés Moya; Fernando Gonzàlez-Candelas
Journal:  Antivir Ther       Date:  2008

4.  The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.

Authors:  Phillip S Pang; Paul J Planet; Jeffrey S Glenn
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

5.  Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t.

Authors:  Chunhua Li; Ling Lu; Xianghong Wu; Chuanxi Wang; Phil Bennett; Teng Lu; Donald Murphy
Journal:  J Gen Virol       Date:  2009-04-08       Impact factor: 3.891

6.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Authors:  Doug J Bartels; Yi Zhou; Eileen Z Zhang; Michelle Marcial; Randal A Byrn; Thomas Pfeiffer; Ann M Tigges; Bambang S Adiwijaya; Chao Lin; Ann D Kwong; Tara L Kieffer
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

7.  Nomenclature and numbering of the hepatitis C virus.

Authors:  Carla Kuiken; Peter Simmonds
Journal:  Methods Mol Biol       Date:  2009

8.  Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.

Authors:  Wengang Yang; Yongsen Zhao; Joanne Fabrycki; Xiaohong Hou; Xingtie Nie; Amy Sanchez; Avinash Phadke; Milind Deshpande; Atul Agarwal; Mingjun Huang
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences.

Authors:  Donald G Murphy; Bernard Willems; Marc Deschênes; Nir Hilzenrat; Roger Mousseau; Sidney Sabbah
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

10.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Authors:  Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M Berlin; Sarah K Young; Bongshin Lee; David Heckerman; Jonathan Carlson; Laura L Reyor; Marianna Kleyman; Cory M McMahon; Christopher Birch; Julian Schulze Zur Wiesch; Timothy Ledlie; Michael Koehrsen; Chinnappa Kodira; Andrew D Roberts; Georg M Lauer; Hugo R Rosen; Florian Bihl; Andreas Cerny; Ulrich Spengler; Zhimin Liu; Arthur Y Kim; Yanming Xing; Arne Schneidewind; Margaret A Madey; Jaquelyn F Fleckenstein; Vicki M Park; James E Galagan; Chad Nusbaum; Bruce D Walker; Gerond V Lake-Bakaar; Eric S Daar; Ira M Jacobson; Edward D Gomperts; Brian R Edlin; Sharyne M Donfield; Raymond T Chung; Andrew H Talal; Tony Marion; Bruce W Birren; Matthew R Henn; Todd M Allen
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  16 in total

1.  Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus.

Authors:  Charlotte Hedskog; Krishna Chodavarapu; Karin S Ku; Simin Xu; Ross Martin; Michael D Miller; Hongmei Mo; Evguenia Svarovskaia
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.

Authors:  Marine Karchava; Jesper Waldenström; Monica Parker; Renee Hallack; Lali Sharvadze; Lana Gatserelia; Nikoloz Chkhartishvili; Natia Dvali; Lela Dzigua; Ekaterine Dolmazashvili; Helene Norder; Tengiz Tsertsvadze
Journal:  Hepatol Res       Date:  2015-03-24       Impact factor: 4.288

3.  The full-length genome sequences of nine HCV genotype 4 variants representing a new subtype 4s and eight unclassified lineages.

Authors:  Ling Lu; Yan Xu; Jie Yuan; Chunhua Li; Donald G Murphy
Journal:  Virology       Date:  2015-04-05       Impact factor: 3.616

4.  Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e.

Authors:  Chunhua Li; Ling Lu; Donald G Murphy; Francesco Negro; Hiroaki Okamoto
Journal:  J Gen Virol       Date:  2014-05-02       Impact factor: 3.891

Review 5.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

Review 6.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

7.  Comparison of pyrosequencing, Sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant mycoplasma pneumoniae quasispecies in respiratory specimens.

Authors:  Kwok-Hung Chan; Kelvin K W To; Betsy W K Chan; Clara P Y Li; Susan S Chiu; Kwok-Yung Yuen; Pak-Leung Ho
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

8.  The genetic diversity and evolutionary history of hepatitis C virus in Vietnam.

Authors:  Chunhua Li; Manqiong Yuan; Ling Lu; Teng Lu; Wenjie Xia; Van H Pham; An X D Vo; Mindie H Nguyen; Kenji Abe
Journal:  Virology       Date:  2014-09-03       Impact factor: 3.616

9.  Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.

Authors:  Santseharay Ramirez; Carlota Fernandez-Antunez; Lotte S Mikkelsen; Jannie Pedersen; Yi-Ping Li; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

10.  High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods.

Authors:  Josep Quer; Josep Gregori; Francisco Rodríguez-Frias; Maria Buti; Antonio Madejon; Sofia Perez-del-Pulgar; Damir Garcia-Cehic; Rosario Casillas; Maria Blasi; Maria Homs; David Tabernero; Miguel Alvarez-Tejado; Jose Manuel Muñoz; Maria Cubero; Andrea Caballero; Jose Antonio del Campo; Esteban Domingo; Irene Belmonte; Leonardo Nieto; Sabela Lens; Paloma Muñoz-de-Rueda; Paloma Sanz-Cameno; Silvia Sauleda; Marta Bes; Jordi Gomez; Carlos Briones; Celia Perales; Julie Sheldon; Lluis Castells; Lluis Viladomiu; Javier Salmeron; Angela Ruiz-Extremera; Rosa Quiles-Pérez; Ricardo Moreno-Otero; Rosario López-Rodríguez; Helena Allende; Manuel Romero-Gómez; Jaume Guardia; Rafael Esteban; Javier Garcia-Samaniego; Xavier Forns; Juan Ignacio Esteban
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.